| Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial ST Patil, L Zhang, F Martenyi, SL Lowe, KA Jackson, BV Andreev, ... Nature medicine 13 (9), 1102-1107, 2007 | 1291 | 2007 |
| Pharmacological agents acting at subtypes of metabotropic glutamate receptors DD Schoepp, DE Jane, JA Monn Neuropharmacology 38 (10), 1431-1476, 1999 | 1255 | 1999 |
| Metabotropic glutamate receptors as novel targets for anxiety and stress disorders CJ Swanson, M Bures, MP Johnson, AM Linden, JA Monn, DD Schoepp Nature reviews Drug discovery 4 (2), 131-144, 2005 | 736 | 2005 |
| Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo [3.1. 0] hexane-2, 6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 … JA Monn, MJ Valli, SM Massey, RA Wright, CR Salhoff, BG Johnson, ... Journal of medicinal chemistry 40 (4), 528-537, 1997 | 477 | 1997 |
| Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors DR Helton, JP Tizzano, JA Monn, DD Schoepp, MJ Kallman Journal of Pharmacology and Experimental Therapeutics 284 (2), 651-660, 1998 | 348 | 1998 |
| Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo [3.1. 0] hexane-2, 6-dicarboxylic acid (LY354740 … JA Monn, MJ Valli, SM Massey, MM Hansen, TJ Kress, JP Wepsiec, ... Journal of medicinal chemistry 42 (6), 1027-1040, 1999 | 340 | 1999 |
| Physiological antagonism between 5-hydroxytryptamine2A and group II metabotropic glutamate receptors in prefrontal cortex GJ Marek, RA Wright, DD Schoepp, JA Monn, GK Aghajanian Journal of Pharmacology and Experimental Therapeutics 292 (1), 76-87, 2000 | 338 | 2000 |
| The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats J Cartmell, JA Monn, DD Schoepp Journal of Pharmacology and Experimental Therapeutics 291 (1), 161-170, 1999 | 311 | 1999 |
| LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors DD Schoepp, BG Johnson, RA Wright, CR Salhoff, NG Mayne, S Wu, ... Neuropharmacology 36 (1), 1-11, 1997 | 250 | 1997 |
| Discovery of Allosteric Potentiators for the Metabotropic Glutamate 2 Receptor: Synthesis and Subtype Selectivity of N-(4-(2-Methoxyphenoxy)phenyl)-N-(2,2,2 … MP Johnson, M Baez, GE Jagdmann, TC Britton, TH Large, DO Callagaro, ... Journal of medicinal chemistry 46 (15), 3189-3192, 2003 | 228 | 2003 |
| Inhibition of cyclic AMP formation by a selective metabotropic glutamate receptor agonist DD Schoepp, BG Johnson, JA Monn Journal of neurochemistry 58 (3), 1184-1186, 1992 | 186 | 1992 |
| In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders LM Rorick-Kehn, BG Johnson, KM Knitowski, CR Salhoff, JM Witkin, ... Psychopharmacology 193, 121-136, 2007 | 181 | 2007 |
| In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats G Battaglia, JA Monn, DD Schoepp Neuroscience letters 229 (3), 161-164, 1997 | 176 | 1997 |
| Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine J Cartmell, JA Monn, DD Schoepp Psychopharmacology 148, 423-429, 2000 | 133 | 2000 |
| Neuroprotection by metabotropic glutamate receptor agonists: LY354740, LY379268 and LY389795 AE Kingston, MJ O'Neill, A Lam, KR Bales, JA Monn, DD Schoepp European journal of pharmacology 377 (2-3), 155-165, 1999 | 131 | 1999 |
| LY354740: a metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats DR Helton, JP Tizzano, JA Monn, DD Schoepp, MJ Kallman Neuropharmacology 36 (11-12), 1511-1516, 1997 | 124 | 1997 |
| Comparison of (1S, 3R)-1-aminocyclopentane-1, 3-dicarboxylic acid (1S, 3R-ACPD)-and 1R, 3S-ACPD-stimulated brain phosphoinositide hydrolysis DD Schoepp, BG Johnson, RA True, JA Monn European Journal of Pharmacology: Molecular Pharmacology 207 (4), 351-353, 1991 | 119 | 1991 |
| Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist … LM Rorick-Kehn, BG Johnson, JL Burkey, RA Wright, DO Calligaro, ... Journal of Pharmacology and Experimental Therapeutics 321 (1), 308-317, 2007 | 118 | 2007 |
| Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia MJ Fell, DL McKinzie, JA Monn, KA Svensson Neuropharmacology 62 (3), 1473-1483, 2012 | 113 | 2012 |
| Neuroprotective effects of LY379268, a selective mGlu2/3 receptor agonist: investigations into possible mechanism of action in vivo A Bond, NM Jones, CA Hicks, GM Whiffin, MA Ward, MF O'Neill, ... Journal of Pharmacology and Experimental Therapeutics 294 (3), 800-809, 2000 | 110 | 2000 |
Gerard MarekGilgamesh PharmaceuticalsVerified email at gilgameshpharmaceutical.com
